Bolt Biotherapeutics, Inc. Deferred Revenue
Bolt Biotherapeutics, Inc. (BOLT) had Deferred Revenue of $819.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-11
- 2026-06-30: Deferred Revenue, Current $819.00K.
- 2026-03-31: Deferred Revenue, Current $630.00K.
- 2025-12-31: Deferred Revenue, Current $449.00K.
- 2025-09-30: Deferred Revenue, Current $1.91M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $819.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $630.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $449.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.51M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $3.08M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $3.02M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.97M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.02M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.91M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.20M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.94M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.69M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.60M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.99M 10-K · filed 2024-03-21 |
| 2022-09-30 | $3.17M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.51M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $3.45M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.87M 10-K · filed 2023-03-29 |
| 2021-09-30 | $5.21M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.33M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.50M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.50M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |